Solicite una cita

Harry H. Yoon, M.D.

  1. Oncologist

Publicaciones

  1. Zhu M, Sonbol MB, Yoon HH. Trifluridine/tipiracil plus ramucirumab in gastric cancer. Lancet Gastroenterol Hepatol. 2021 Mar; 6 (3):154-155 Epub 2021 Jan 26
    View PubMed
  2. Childs DS, Yoon HH, Eiring RA, Jin Z, Jochum JA, Pitot HC, Jatoi A. Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer. Support Care Cancer. 2021 Feb; 29 (2):733-739 Epub 2020 May 24
    View PubMed
  3. Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Transl Oncol. 2021 Feb; 14 (2):100973 Epub 2020 Dec 15
    View PubMed
  4. Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol. 2020 Sep-Oct; 5 (5):951-958 Epub 2020 Apr 27
    View PubMed
  5. Garant A, Whitaker TJ, Spears GM, Routman DM, Harmsen WS, Wilhite TJ, Ashman JB, Sio TT, Rule WG, Neben Wittich MA, Martenson JA, Tryggestad EJ, Yoon HH, Blackmon S, Merrell KW, Haddock MG, Hallemeier CL. A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal Cancer. Pract Radiat Oncol. 2019 Nov; 9 (6):410-417 Epub 2019 July 13
    View PubMed
  6. Bendell J, Yoon HH. Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer UpToDate [Internet] (updated continuously and peer-reviewed, Yoon HH has been coauthor since 2012). Most Recent Update 2020.
  7. Bendell J, Yoon HH. Progressive, locally advanced unresectable, and metastatic esophageal and gastric cancer: Approach to later lines of systemic therapy UpToDate [Internet] (updated continuously and peer-reviewed, Yoon HH has been coauthor since 2012). Most Recent Update 2020. 2019.
  8. Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019 Jul; 22 (4):828-837 Epub 2019 Mar 25
    View PubMed
  9. Jin Z, Holubek M, Sukov WR, Sattler CA, Wiktor AE, Jenkins RB, Wu TT, Yoon HH. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. Am J Clin Oncol. 2019 Feb; 42 (2):190-195
    View PubMed
  10. Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA. Intertumoral Heterogeneity of CD3(+) and CD8(+) T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. Clin Cancer Res. 2019 Jan 1; 25 (1):125-133 Epub 2018 Oct 09
    View PubMed
  11. Routman DM, Garant A, Lester SC, Day CN, Harmsen WS, Sanheuza CT, Yoon HH, Neben-Wittich MA, Martenson JA, Haddock MG, Hallemeier CL, Merrell KW. A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. Adv Radiat Oncol. 2019 Jan-Mar; 4 (1):63-69 Epub 2019 Jan 17
    View PubMed
  12. Yoon H, Karapetyan L, Choudhary A, Kosozi R, Bali GS, Zaidi AH, Atasoy A, Forastiere AA, Gibson MK. Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma. Oncologist. 2018 Sep; 23 (9):1004-e102 Epub 2018 May 16
    View PubMed
  13. Chakrabarti S, Dong H, Paripati HR, Ross HJ, Yoon HH. First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. Oncologist. 2018 Jul; 23 (7):840-843 Epub 2018 Apr 19
    View PubMed
  14. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10; 4 (5):e180013
    View PubMed
  15. Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017 Dec 1; 28 (12):2932-2942
    View PubMed
  16. Yoon HH. Novel treatment strategies in carcinoma of unknown primary. Ann Oncol. 2017 Oct; 28 Suppl 9:ix25
    View PubMed
  17. Jin Z, Yoon HH. Antiangiogenic Therapy in Gastroesophageal Cancer. Hematol Oncol Clin North Am. 2017 Jun; 31 (3):499-510 Epub 2017 Mar 22
    View PubMed
  18. Yoon HH, Bendell JC, Wainberg ZA. Consideration of an association between performance status and ramucirumab efficacy. Ann Oncol 2017 Apr 1; 28 (4):902-903
    View PubMed
  19. Childs DS, Jacobson AC, Mitchell JL, Hubbard JM, Yoon HH, Finnes H, Grothey A, Jatoi A. Prescriber adherence to antiemetic guidelines with the new agent trifuridine-tipiracil Journal of Community and Supportive Oncology. 2017; 15: (3)e142-6.
  20. Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016 Dec; 27 (12):2196-2203 Epub 2016 Oct 20
    View PubMed
  21. Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Int J Cancer. 2016 Oct 1; 139 (7):1626-31 Epub 2016 June 10
    View PubMed
  22. Jin Z, Yoon HH. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol. 2016 Oct; 7 (5):771-788
    View PubMed
  23. Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, Prow DM, Reynolds CM, Marchello BT, Mowat RB, Mattar BI, Erlichman C, Goetz MP. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol. 2016 Feb; 27 (2):339-44 Epub 2015 Nov 16
    View PubMed
  24. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015 Dec 1; 21 (23):5294-304 Epub 2015 July 17
    View PubMed
  25. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst. 2015 Oct; 107 (10) Epub 2015 July 09
    View PubMed
  26. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014 Jun 1; 20 (11):3033-43 Epub 2014 Mar 31
    View PubMed
  27. Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 2014 Feb 1; 120 (3):415-24 Epub 2013 Oct 21
    View PubMed
  28. Yoon HH. HER2 in Esophagogastric Adenocarcinoma. Int J Targeted Ther Cancer 2013.2013;2:(5)54-61.
  29. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012 Nov 10; 30 (32):3932-8 Epub 2012 Sept 17
    View PubMed
  30. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012 Feb 1; 30 (4):406-12 Epub 2011 Dec 27
    View PubMed
  31. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18 (2):546-54
    View PubMed
  32. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One. 2012; 7 (8):e42274 Epub 2012 Aug 06
    View PubMed
  33. Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 1; 29 (34):4561-7 Epub 2011 Oct 11
    View PubMed
  34. Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011 Oct; 68 (4):863-70 Epub 2011 Feb 01
    View PubMed
  35. Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, Meltzer SJ, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011 May 17; 11:176
    View PubMed
  36. Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010 Dec; 85 (12):1080-9
    View PubMed
  37. Yoon HH, Lowe VJ, Cassivi SD, Romero Y. The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. Gastroenterol Clin North Am. 2009 Mar; 38 (1):105-20, ix
    View PubMed
  38. Yoon HH, Gibson MK. Induction Chemotherapy Encyclopedia of Cancer 2008 (Living Reference Work Entry [updated 2015]; ed. Manfred Schwab); doi: 10.1007/978-3-642-27841-9_3040-2.2008;pp1-3.
  39. Yoon HH, Forastiere AA. Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future Oncol. 2008 Jun; 4(3):413-25.
    View PubMed
  40. Yoon HH. Adapting to duty-hour limits--four years on. N Engl J Med. 2007 Jun 28; 356(26):2668-70.
    View PubMed
  41. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer. 2006 Apr 15; 106(8):1677-84.
    View PubMed
  42. Yoon HH, Kwon HL, Mattson RH, Spencer DD, Spencer SS. Long-term seizure outcome in patients initially seizure-free after resective epilepsy surgery. Neurology. 2003 Aug 26; 61(4):445-50.
    View PubMed
PST-20225353